Summary of findings 2. MFS‐LE versus S‐LE for parenterally fed preterm infants.
| MFS‐LE versus S‐LE for parenterally fed preterm infants(comparison 2) | ||||||
|
Population: Parenterally fed preterm infants
Intervention: MFS‐LE Comparison: S‐LE | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | Number of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| S‐LE (control) | MFS‐LE | |||||
| Death before discharge Follow‐up: birth until discharge |
Moderate risk^ (based on median control risk in S‐LE group in all studies) |
RR 5 (0.25 to 99.95) | 60 (1 study) | ⊕⊕⊝⊝ low1,2 | Downgraded 2 levels for imprecision | |
| 73 per 1000# | 365 per 1000 (18 to 1000) | |||||
| Days to regain birth weight Follow‐up: birth until discharge | The mean days to regain birth weight in the control group was 11 days | The mean days to regain birth weight in the intervention groups was 1 day lower (3.6 lower to 1.6 higher) | 57 (1 study) | ⊕⊕⊝⊝ low1,3 | Downgraded 2 levels for imprecision | |
|
Rate of weight gain (g/kg/day) Follow‐up: birth until 3 weeks |
The mean rate of weight gain (g/kg/day) in the control group was 5.6 g/kg/day | The mean rate of weight gain (g/kg/day) in the intervention groups was 1.67 g/kg/day lower (7.01 lower to 3.67 higher) |
57 (1 study) | ⊕⊕⊝⊝ low1,3 | Downgraded 2 levels for imprecision |
|
| Bronchopulmonary dysplasia/chronic lung disease Follow‐up: birth until discharge | Study population | RR 1.39 (0.42 to 4.65) | 57 (1 study) | ⊕⊕⊝⊝ low1,2 | Downgraded 2 levels for imprecision |
|
| 133 per 1000 | 185 per 1000 (56 to 620) | |||||
| Any sepsis (clinical and/or culture positive) Follow‐up: birth until discharge | Study population | RR 1.11 (0.31 to 4.02) | 57 (1 study) | ⊕⊕⊝⊝ low1,2 | Downgraded 2 levels for imprecision |
|
| 133 per 1000 | 148 per 1000 (41 to 536) | |||||
| Parenteral nutrition‐associated liver disease/cholestasis Follow‐up: birth until discharge | Moderate risk (based on median control risk in S‐LE group in all studies)^ | RR 3.32 (0.14 to 78.25) | 57 (1 study) | ⊕⊕⊝⊝ low1,2 | Downgraded 2 levels for imprecision |
|
| 42 per 1000 | 139 per 1000 (6 to 1000) | |||||
| *The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). ^The control rate was 0 for this outcome therefore the 'median control group risk' in all infants treated with S‐LE in all included studies (‘all alternative LE’) was used for calculating the corresponding risk . MFS‐LE: medium chain triglycerides‐fish‐soy lipid emulsion; S‐LE: soy lipid emulsion; CI: confidence interval; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Optimal information size (OIS) not achieved. 2 Confidence intervals cross 0.75 or 1.25. 3 Wide confidence intervals crossing appreciable harm and benefit.